Jürgen Behr

1990–2025 年に発表

182
論文数
27,631
被引用数
78
h 指数
165
i10 指数

被引用数

Jürgen Behr の年別被引用数1960 年: 被引用 2 件1993 年: 被引用 2 件1994 年: 被引用 2 件1996 年: 被引用 2 件1997 年: 被引用 6 件1998 年: 被引用 7 件1999 年: 被引用 15 件2000 年: 被引用 17 件2001 年: 被引用 28 件2002 年: 被引用 24 件2003 年: 被引用 43 件2004 年: 被引用 58 件2005 年: 被引用 69 件2006 年: 被引用 82 件2007 年: 被引用 77 件2008 年: 被引用 125 件2009 年: 被引用 103 件2010 年: 被引用 90 件2011 年: 被引用 77 件2012 年: 被引用 80 件2013 年: 被引用 115 件2014 年: 被引用 109 件2015 年: 被引用 113 件2016 年: 被引用 142 件2017 年: 被引用 152 件2018 年: 被引用 169 件2019 年: 被引用 877 件2020 年: 被引用 1,080 件2021 年: 被引用 1,188 件2022 年: 被引用 1,086 件2023 年: 被引用 797 件2024 年: 被引用 1,330 件2025 年: 被引用 544 件2026 年: 被引用 16 件1961〜1992 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,504 件、この内訳の 22%ドイツ: 引用元論文 946 件、この内訳の 8.3%中国: 引用元論文 931 件、この内訳の 8.2%イギリス: 引用元論文 870 件、この内訳の 7.6%イタリア: 引用元論文 713 件、この内訳の 6.2%日本: 引用元論文 588 件、この内訳の 5.1%フランス: 引用元論文 544 件、この内訳の 4.8%カナダ: 引用元論文 493 件、この内訳の 4.3%オーストラリア: 引用元論文 338 件、この内訳の 3%オランダ: 引用元論文 328 件、この内訳の 2.9%スペイン: 引用元論文 320 件、この内訳の 2.8%スイス: 引用元論文 237 件、この内訳の 2.1%
0%22%その他 22.7%

分野

  • Medicine81.4%
  • Biochemistry, Genetics and Molecular Biology8.6%
  • Immunology and Microbiology3%
  • Neuroscience1.8%
  • Agricultural and Biological Sciences1.4%
  • Engineering0.8%
  • その他3%

トピック

  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis18.2%
  • Pulmonary Hypertension Research and Treatments5.3%
  • Chronic Obstructive Pulmonary Disease (COPD) Research4.9%
  • Systemic Sclerosis and Related Diseases4.5%
  • Sarcoidosis and Beryllium Toxicity Research3.2%
  • Medical Imaging and Pathology Studies2.6%
  • その他61.3%

共著者

全論文

検索で開く
  1. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Moisés Selman, William D. Travis, Simon Walsh, Kevin C. Wilson - American Journal of Respiratory and Critical Care Medicine 2018 被引用: 4,100

  2. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shandra Protzko, Ganesh Raghu, Luca Richeldi, Nicola Sverzellati, Jeffrey J. Swigris, Dominique Valeyre - American Journal of Respiratory and Critical Care Medicine 2013 被引用: 4,273

  3. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 被引用: 748

  4. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2016 被引用: 1,444

  5. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Klaus F. Rabe, Francesco Bonella, R. Bonnet, Christian Grohé, Matthias Held, Heinrike Wilkens, Peter Hammerl, Dirk Koschel, Stefan Blaas, Hubert Wirtz, Joachim H. Ficker, Wolfgang Neumeister, N Schönfeld, Martin Claussen, Nikolaus Kneidinger, Marion Frankenberger, Simone Hummler, Nicolas Kahn, Silke Tello, Julia Freise, Tobias Welte, Petra Neuser, Andreas Günther, Carmen Schade‐Brittinger, Behnaz Aminossadati, Christian Nasemann, Soraya Yahiaoui, Christoph Dupuy Backofen, Maik Hahmann, Michael Wittenberg, Fotis Drakopanagiotakis, Daniel von der Beck, Stefanie Ghofrani, S Heinemann, Ekaterina Krauss, Hella Rethorn, Andrea Koch, Gabriela Leuschner, Sandhya Matthes, Claus Neurohr, Tobias Veit, Katrin Milger, Felix Herth, Julia Benstz, Simone Hummler, Thomas Bahmer, Heike Biller, Benjamin Waschki, Rosa-Marie Apel, Ulrich Costabel, Eva Börner, Thomas Wessendorf, M. Arnrich, Lacramioara Ilie, Alexandra Wald, Hans‐Jürgen Seyfarth, Christian Reinhardt, Atif Cinar, Markus Vogler, Siegfried Matthias Huhn, Jaqueline Richter, U Neff, Torsten Blum, Silvan Vesenbeckh, Christian Boch, Hannes Semper, Andreas Wilke, Michael Pfeifer, Annette Schweda, Angelika Krill ほか 7 名 - The Lancet Respiratory Medicine 2021 被引用: 516

  6. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

    著者: , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2019 被引用: 241

  7. Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review

    著者: , , , , , , , , , , - Radiation Oncology 2020 被引用: 235

  8. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort

    著者: , , , , , , , , , , , , , , , - The Journal of Allergy and Clinical Immunology In Practice 2023 被引用: 86

  9. A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

    著者: , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2022 被引用: 101

  10. Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gerald Burgstaller, Herbert B. Schiller - Science Translational Medicine 2023 被引用: 79

  11. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

    著者: , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2020 被引用: 134

  12. The Diagnosis and Treatment of COPD and Its Comorbidities.

    著者: , , , - Deutsches Ärzteblatt international 2023 被引用: 117

  13. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

    著者: , , , - European Respiratory Journal 2015 被引用: 463

  14. Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fabian J. Theis, Gerald Burgstaller, Herbert B. Schiller - European Respiratory Journal 2024 被引用: 101

  15. Inhaled Iloprost for Severe Pulmonary Hypertension

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2002 被引用: 1,781

  16. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry

    著者: , , , , , , , , , , , , , , , , , , , , , , , - European Respiratory Journal 2020 被引用: 189

  17. Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis

    著者: , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2018 被引用: 187

  18. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

    著者: , , , , , , , , - New England Journal of Medicine 2018 被引用: 259

  19. Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers

    著者: , , , , , , , , , , , , , , , , , , , , , , - EMBO Molecular Medicine 2021 被引用: 103

  20. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jessica Shore, Marlies Wijsenbeek, Robert S. Brown, Daniel Grogan, Dorothy Ivey, Patrycja Golińska, Banu A. Karimi-Shah, Fernando J. Martínez - American Journal of Respiratory and Critical Care Medicine 2024 被引用: 76

  21. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis

    著者: , , , , , , , , , , , - Respiratory Research 2018 被引用: 142

  22. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

    著者: , , , , , , - Scientific Reports 2021 被引用: 72

  23. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis

    著者: , , , , , , , , , - BMJ Open Respiratory Research 2022 被引用: 67

  24. BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis

    著者: , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2007 被引用: 498